

**PD DR. THOMAS WERLEN**



PD Dr. Thomas Werlen is the Managing Partner of the Quinn Emanuel (QE) Zurich office. Qualified in both New York and Switzerland and having worked at the highest levels in New York, London and Switzerland, Thomas Werlen has more than 20 years of experience in both common and civil law.

Thomas's practice at QE focuses on white collar criminal law as well as on complex civil disputes, often involving multiple jurisdictions.

Thomas regularly represents clients in high-stakes white collar matters. For instance, he has been representing FIFA in criminal investigations being pursued in the U.S. and Switzerland, as well as several major Swiss banking and financial institutions in matters adverse to Swiss and U.S. authorities in connection with the U.S. Swiss Tax Program and with the fall-out of the "Panama Papers". Thomas is also advising a number of high-profile clients in connection with the 1MDB, PDVSA and Lava Jato criminal and regulatory investigations, including major financial institutions in Switzerland and a large Swiss-based commodities trading company.

In the civil dispute resolution context, Thomas recently advised the majority shareholder of Sika AG in a multibillion cross-border acquisition dispute, and Swiss private banking group EFG International in a series of complex financial disputes in the U.S., Europe and Asia. Thomas has also been acting as arbitrator and expert in complex financial arbitrations and in pharma and life sciences disputes. Reflecting his extensive financial and capital markets experience, Thomas was appointed as market expert on the Panel of Recognized International Markets Experts in Finance (P.R.I.M.E. Finance) based in The Hague.

Prior to joining Quinn Emanuel in 2012, Thomas served for six years as Group General Counsel and a member of the Executive Committee for Novartis where he oversaw a global team of over 750 people spread across 140 jurisdictions. His work covered all areas of litigation affecting a multinational company with a U.S. listing in the heavily regulated pharmaceutical industry, including the 50 bn plus acquisition by Novartis of Alcon and the related debt capital markets financings in the 30 bn plus range.

Before joining Novartis, Thomas was a partner in the international finance and the corporate and capital markets groups at Allen & Overy in London from 2000 until 2006. Prior to that, he was a Senior Associate at Davis Polk & Wardwell LLP in London and at Cravath, Swaine & Moore in New York and London. His work focused on derivatives, debt (straight bonds, high-yield, ABS) and equity capital markets (IPO's and rights offerings), structured finance, banking (loan agreements for investment grade and below investment grade borrowers); his clients included both global investment banks and corporations. He was also involved in regulatory matters including the SEC, the CFTC and various other capital markets regulators. Thomas was repeatedly named as one of the leading U.S. international capital markets practitioners by various leading magazines and has been the recipient of numerous awards during his career.

Thomas holds Lic. iur. and Dr. iur. Degrees in law from the University of Zurich and a Master's Degree in law from Harvard Law School. He is a member of the New York and the Swiss bar. Ever since 1995, Thomas has been teaching international banking and finance law at the Universities of Zurich and St. Gallen. Since 2013, he has been a teaching professor at the University of St. Gallen. He was a member of the Regulatory Board of the SIX Swiss Exchange AG from 2008 – 2012 and now serves on the complaint commission of SIX Swiss Exchange AG. Thomas is a Member of the Panel of Experts for P.R.I.M.E. Finance.